Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

scientific article published on August 3, 2010

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1212/WNL.0B013E3181EBDD79
P8608Fatcat IDrelease_svtaezhqonfrpkyxfo6f6ksy44
P953full work available at URLhttps://europepmc.org/articles/pmc2918470?pdf=render
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20679638/pdf/?tool=EBI
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20679638/?tool=EBI
http://intl.neurology.org/cgi/content/abstract/75/5/448
https://europepmc.org/articles/PMC2918470
https://europepmc.org/articles/PMC2918470?pdf=render
https://doi.org/10.1212/wnl.0b013e3181ebdd79
https://www.neurology.org/doi/pdfdirect/10.1212/WNL.0b013e3181ebdd79
P932PMC publication ID2918470
P698PubMed publication ID20679638

P50authorThomas Ten HaveQ57327797
Matthew B. SternQ67208124
P2093author name stringH. I. Hurtig
T. R. Ten Have
D. Weintraub
A. Colcher
J. E. Duda
S. Mavandadi
E. Mamikonyan
A. D. Siderowf
S. S. Horn
S. Nazem
P2860cites workActa Neurologica ScandinavicaQ4676732
Primary versus secondary insomnia in older adults: subjective sleep and daytime functioningQ48691209
Reliability, validity, and clinical correlates of apathy in Parkinson's diseaseQ48852465
Depression and disability in Parkinson's disease.Q51003628
Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study.Q51974389
Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.Q52015908
Augmentation With Open-Label Atomoxetine for Partial or Nonresponse to AntidepressantsQ56386964
9/Geriatric Depression Scale (GDS)Q56780750
Anti-depressive treatment in Parkinson's disease. A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPAQ64791376
Recognition and treatment of depression in Parkinson's diseaseQ73926182
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humansQ24654140
“Mini-mental state”Q25938989
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness ScaleQ28256570
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practiceQ29614979
Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson diseaseQ33516505
Provisional diagnostic criteria for depression of Alzheimer diseaseQ34121328
Augmentation with open-label atomoxetine for partial or nonresponse to antidepressantsQ34464019
Diagnostic criteria for Parkinson diseaseQ34489839
What contributes to quality of life in patients with Parkinson's disease?Q35459164
Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trialQ35485478
An examination of executive dysfunction associated with frontostriatal circuitry in Parkinson's diseaseQ35684460
Antidepressant studies in Parkinson's disease: a review and meta-analysisQ36008775
Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work GroupQ36279999
Norepinephrine: The redheaded stepchild of Parkinson's diseaseQ36784705
A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's diseaseQ36961731
A controlled trial of antidepressants in patients with Parkinson disease and depressionQ37180389
Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study.Q37196231
Specific tricyclic antidepressant binding sites in rat brainQ41752061
Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseasesQ42438205
The Inventory of Depressive Symptomatology (IDS): psychometric properties.Q42635264
Effect of reboxetine on depression in Parkinson's disease patients.Q43986305
Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's diseaseQ44351576
Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortexQ44418380
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled studyQ46724727
Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorderQ48099054
The locus ceruleus and dementia in Parkinson's diseaseQ48289979
The role of locus coeruleus in the regulation of cognitive performanceQ48301222
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectParkinson's diseaseQ11085
atomoxetineQ417240
P304page(s)448-455
P577publication date2010-08-01
2010-08-03
P1433published inNeurologyQ1161692
P1476titleAtomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease
P478volume75

Reverse relations

cites work (P2860)
Q64864842Q64864842
Q92582730A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease
Q35043846A meta-analysis of randomised placebo-controlled treatment trials for depression and anxiety in Parkinson's disease
Q37862761A précis of recent advances in the neuropsychology of mild cognitive impairment(s) in Parkinson's disease and a proposal of preliminary research criteria
Q30240991A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.
Q38571668Advances in the treatment of cognitive impairment in Parkinson's disease
Q64861761Antidepressants for Depression, Apathy, and Gait Instability in Parkinson's Disease: A Multicenter Randomized Study
Q43491031Anxiety and depression in Parkinson's disease
Q39777480Apathy and Parkinson's disease
Q39665359Apathy in Parkinson's disease: diagnostic and etiological dilemmas
Q90641261Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis
Q85359306Canadian Guidelines on Parkinson's Disease
Q38770352Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system
Q48642615Clinical trials of dementia with Lewy bodies and Parkinson's disease dementia
Q41540738Cognitive Function in Parkinson's Disease Patients with and without Anxiety
Q28073680Cognitive Training in Parkinson's Disease: A Review of Studies from 2000 to 2014
Q38751099Cognitive decline in Parkinson disease
Q38206496Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective
Q34307633Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?
Q37364568Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis
Q37968511Cognitive impairment in nondemented Parkinson's disease
Q38027731Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment
Q35009609Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis
Q41317541Comprehensive treatment of dementia with Lewy bodies
Q37971293Depression in Parkinson disease--epidemiology, mechanisms and management.
Q38116807Depression in Parkinson's disease: identification and management
Q38265929Depression in Parkinson's disease: the effectiveness and risk of pharmacotherapy. Clinical review
Q62719741Depression, Apathy, Anhedonia, and Fatigue in Parkinson’s Disease
Q37593613Distant delivery of a mindfulness-based intervention for people with Parkinson's disease: the study protocol of a randomised pilot trial
Q49126482Dopamine selectively remediates 'model-based' reward learning: a computational approach
Q38067142Drug treatments for the neuropsychiatric complications of Parkinson's disease
Q36010298DrugGenEx-Net: a novel computational platform for systems pharmacology and gene expression-based drug repurposing
Q38875190Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer's Disease
Q47319471Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis
Q33765388Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis
Q38797335Emotional manifestations of PD: Neurobiological basis
Q47651254Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.
Q28833274Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study
Q39754744Frontostriatal cognitive staging in Parkinson's disease
Q47793861Imaging the Etiology of Apathy, Anxiety, and Depression in Parkinson's Disease: Implication for Treatment
Q35264006Improving response inhibition in Parkinson's disease with atomoxetine
Q37331607Impulsivity and apathy in Parkinson's disease
Q38225930Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies
Q39100264Management of sleep disorders in Parkinson's disease and multiple system atrophy
Q55387790Mild Cognitive Impairment in Parkinson's Disease-What Is It?
Q37864573Mild cognitive impairment in Parkinson's disease.
Q35165280Monoamine reuptake inhibitors in Parkinson's disease
Q34135756Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study
Q35028706Neurobiology of depression and anxiety in Parkinson's disease
Q89736107Neuropsychiatric Disorders in Parkinson's Disease: What Do We Know About the Role of Dopaminergic and Non-dopaminergic Systems?
Q38799051Neuropsychiatric Issues in Parkinson's Disease
Q34089583Neuropsychological outcomes after psychosocial intervention for depression in Parkinson's disease
Q39323947New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson's Disease
Q38075712New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease
Q35013240Noradrenaline and Parkinson's disease
Q55004525Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases-An Overview of Imaging Studies.
Q38091914Noradrenergic modulation of cognition: therapeutic implications
Q38258228Norepinephrine deficiency in Parkinson's disease: the case for noradrenergic enhancement
Q38258699Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease
Q34618993Off-label use of atomoxetine in adults: is it safe?
Q31080551Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
Q30239814Parkinson's Disease and Cognitive Impairment
Q36351543Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications
Q36186763Parkinson's disease dementia: a neural networks perspective
Q35614156Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa
Q33917094Parkinson's disease: the quintessential neuropsychiatric disorder
Q38588201Psychiatric Conditions in Parkinson Disease: A Comparison With Classical Psychiatric Disorders.
Q38206498Psychiatric issues in cognitive impairment
Q38998475Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases
Q91995417Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson's disease
Q38290962Sleep disturbances and dementia
Q91268058Statistical advances in clinical trials and clinical research
Q38070888Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease.
Q33784038Targeting impulsivity in Parkinson's disease using atomoxetine
Q36998284Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.
Q33607256The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
Q64767922The Neuropsychiatry of Parkinson Disease: A Perfect Storm
Q42248817The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease
Q26799352The impact of neuroscience on society: cognitive enhancement in neuropsychiatric disorders and in healthy people
Q64972290The pharmacologic management of depression in Parkinson's disease.
Q35276597Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection
Q38593798Therapy-resistant symptoms in Parkinson's disease
Q48821094Treatment of Apathy in Huntington's Disease and Other Movement Disorders
Q39342961Treatment of Sleep Dysfunction in Parkinson's Disease.
Q34388686Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease
Q30358337Treatment of psychosis and dementia in Parkinson's disease.
Q48109363Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease
Q52886915[Antidepressants for treatment of depression in palliative patients : a systematic literature review].
Q87424086[Coexistent depressive and anxiety disorders in neurological diseases: from a perspective of multimorbidity]
Q27021220Mild cognitive impairment in Parkinson's disease.

Search more.